Increased reporting of interstitial pneumonitis with combined EGFR-TKI and PD-1/PD-L1 inhibitor therapy in NSCLC: a pharmacovigilance analysis of 67,818 reports. (PubMed, Front Immunol) - Sep 13, 2026 - "Agent-specific variation was observed: durvalumab plus EGFR-TKI (IP reporting proportion, 47.22%; aOR, 16.58; 95% CI, 7.89-35.51) and nivolumab plus EGFR-TKI (IP reporting proportion, 21.05%; aOR, 4.26; 95% CI, 2.57-6.79) showed the highest reporting odds, whereas pembrolizumab plus EGFR-TKI (3.85%) and atezolizumab plus EGFR-TKI (5.06%) did not show significantly increased reporting odds; these small combination subgroups are exploratory. As a spontaneous-reporting study without a defined denominator, these findings reflect a reporting association and safety signal rather than a confirmed clinical risk estimate. They support continued pharmacovigilance and prospective studies to clarify the safety of combining these therapies in NSCLC."
Adverse events • Journal • Observational data • Retrospective data • Inflammation • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Solid Tumor
|